Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 44.8% in October

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 66,000 shares, a decrease of 44.8% from the October 15th total of 119,500 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily volume of 130,800 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BOLT. Assenagon Asset Management S.A. purchased a new position in Bolt Biotherapeutics in the second quarter worth $26,000. FMR LLC raised its position in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after acquiring an additional 28,773 shares in the last quarter. Finally, Acuitas Investments LLC raised its position in Bolt Biotherapeutics by 21.7% in the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock worth $473,000 after acquiring an additional 112,555 shares in the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Trading Down 9.1 %

Shares of Bolt Biotherapeutics stock traded down $0.06 during trading hours on Friday, hitting $0.57. 376,825 shares of the company were exchanged, compared to its average volume of 165,925. Bolt Biotherapeutics has a 1 year low of $0.55 and a 1 year high of $1.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 4.28. The business has a 50-day moving average of $0.64 and a 200-day moving average of $0.74.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.02 million. On average, equities research analysts expect that Bolt Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bolt Biotherapeutics currently has an average rating of “Hold” and an average price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.